Molecular Partners AG Price to Book Ratio

Molecular Partners AG (MOLN) currently reports a P/B ratio of 4.13. That is below the Healthcare sector average of 6.23. Use the charts on this page to explore Molecular Partners AG's P/B ratio history and peer comparisons.

Molecular Partners AG's P/B ratio of 4.13 is lower than the Healthcare sector average of 6.23. That is roughly 33.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/B ratio is a valuation multiple that relates Molecular Partners AG's market price to a fundamental measure such as earnings, sales, or book value. At 4.13, MOLN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/B ratio of 4.13, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 6.23. From there, open related valuation or income-statement pages for Molecular Partners AG, and consider following MOLN for alerts when major investors trade the stock.

Molecular Partners AG is classified in the Healthcare sector. On P/B ratio, it currently shows 4.13 versus a sector average near 6.23. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MOLN with unrelated industries.